Neumora Earnings|Guidance|M&A|Buyback|Dividend|Leadership|Restructuring|Regulatory|Legal|Cyber|Offering|Bankruptcy|Other Monday, November 16, 2026 +0.70 Positive

Neumora submits IND for NMRA-215 obesity treatment; MAD data supports NMRA-511 dosing

Neumora submitted an IND for the obesity treatment NMRA-215 and presented positive MAD results for NMRA-511, while updating the market on its pipeline. This announcement affects the company's financial guidance prospects and business development trajectory.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed